TAPENTADOL
tapentadol 50 mg modified release tablet, 28
TAPENTADOL (10096J)
10096J
Body System:
Manner of administration:Oral
Restriction 10755
Indication: Chronic severe pain
Treatment phase: Initial PBS treatment after 1 June 2020 where patient has been treated with opioids
for less than 12 months
Restriction 10748
Indication: Chronic severe pain
Treatment phase: Initial PBS treatment after 1 June 2020 where patient has been treated with opioids
for more than 12 months
Restriction 10752
Indication: Chronic severe pain
Treatment phase: Continuing PBS treatment after 1 June 2020
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 28 | # of repeats: 0 | DPMQ: $29.60 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Palexia SR | |||||